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Key messages
What is already known about this subject?
 ► Combined pulmonary fibrosis and emphysema 
(CpFe) was observed in short-survival IpF patients 
and in SSc subjects with a relevant decrease in FVC 
and a DLco.
What does this study add?
 ► this is the first study describing a more reduced 
survival in SSc-CpFe compared with other SSc 
subgroups.
How might this impact on clinical practice?
 ► CpFe is a radiological pattern that should always be 
considered in SSc chest Ct assessment
 ► CpFe detection can be useful in order to select pa-
tients with a more severe SSc.
AbstrAct
Objectives this multicentre study aimed to investigate 
the overall mortality of combined pulmonary fibrosis and 
emphysema (CpFe) in systemic sclerosis (SSc) and to 
compare CpFe-SSc characteristics with those of other SSc 
subtypes (with interstitial lung disease—ILD, emphysema 
or neither).
Methods Chest Cts, anamnestic data, immunological 
profile and pulmonary function tests of patients with SSc 
were retrospectively collected. each chest Ct underwent 
a semiquantitative assessment blindly performed by 
three radiologists. patients were clustered in four groups: 
SSc-CpFe, SSc-ILD, SSc-emphysema and other-SSc 
(without ILD nor emphysema). the overall mortality of 
these groups was calculated by Kaplan-Meier method and 
compared with the stratified log-rank test; Kruskal-Wallis 
test, t-Student test and χ² test assessed the differences 
between groups. p<0.05 was considered statistically 
significant.
Results We enrolled 470 patients (1959 patient-year); 
15.5 % (73/470) died during the follow-up. Compared 
with the SSc-ILD and other-SSc, in SSc-CpFe there was 
a higher prevalence of males, lower anticentromere 
antibodies prevalence and a more reduced pulmonary 
function (p<0.05). the Kaplan-Meier survival analysis 
demonstrates a significantly worse survival in patients 
with SSc-CpFe (hr vs SSc-ILD, vs SSc-emphysema and 
vs other-SSc, respectively 1.6 (CI 0.5 to 5.2), 1.6 (CI 0.7 to 
3.8) and 2.8 (CI 1.2 to 6.6).
Conclusions CpFe increases the mortality risk in 
SSc along with a highly impaired lung function. these 
findings strengthen the importance to take into account 
emphysema in patients with SSc with ILD.
InTROduCTIOn
As interstitial lung disease (ILD) increases the 
mortality in systemic sclerosis (SSc),1 many 
studies are focusing on predictive factors of 
survival. Pulmonary function tests (forced 
vital capacity—FVC and diffusion lung 
capacity of CO—DLco) and semiquantitative 
assessment of ILD extension detectable in 
chest CT (sQCT), are the most important.2 In 
particular, FVC and DLco are quite diffused 
and they play a pivotal role in the diagnostic 
and therapeutic decision making process.
Combined pulmonary fibrosis and emphy-
sema (CPFE) is a lung affection characterised 
by the presence of ILD and emphysema. CPFE 
was observed in short-survival IPF patients, 
even non-smokers.3 Other following studies 
supported the hypothesis that emphysema is 
an independent mortality risk factor in ILD.4
Cottin et al. reported 34 cases of CPFE in 
connective tissue disease for the first time.5 In 
the next years, some authors presented cases 
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Table 1 Patients characteristics
Total Other-SSc
SSc-
emphysema SSc-ILD SSc-CPFE P value
n (%) 470 (100) 202 (43) 29 (6) 196 (42) 43 (9) –
Age, mean (year)
(95% CI)
59.2
(57.2 to 60.5)
59.3
(57.3 to 61.3)
59.8
(54.8 to 64.9)
59.4
(57.4 to 61.3)
57.7
(53.3 to 62.1)
nss
Sex (M:F) 90:380 30:172 8:21 36:160 16:27 (CPFE vs SSc-ILD)**
(CPFE vs Other-SSc)***
Disease duration, mean (year) 
(95% CI)
8.2
(7.4 to 8.9)
7.8
(6.6 to 9.0)
8.4
(5.3 to 11.5)
8.4
(7.4 to 9.5)
8.6
(6.1 to 11)
nss
Smoke habit‡ 
(none:former:current)
351:57:52 165:17:19 17:5:6 146:28:18 25:7:9 (CPFE vs Other-SSc)**
(SSc-Emphysema vs Other-SSc)*
ACA prevalence (n) 160 107 21 27 5 (CPFE vs SSc-Other)§
(CPFE vs SSc-Emphysema)§
(SSc-ILD vs SSc-Emphysema)§
(SSc-Other vs SSc-Emphysema)*
(Other-SSc vs SSc-ILD)§
anti Scl70 prevalence (n) 154 23 0 113 18 (CPFE vs SSc-Emphysema)***
(CPFE vs Other-SSc)§
(SSc-ILD vs SSc-Emphysema)§
(SSc-ILD vs Other-SSc)§
FVC-predicted, mean (95% 
CI)
99%
(97 to 102)
109%
(105 to 113)
103%
(92 to 114)
91%
(88 to 95)
88%
(80 to 95)
(CPFE vs Other-SSc)†
(CPFE vs SSc-Emphysema)**
(Other-SSc vs SSc-ILD)†
(SSc-ILD vs SSc-Emphysema)*
TLC-predicted, mean (95% 
CI)
93%
(90 to 95)
99%
(96 to 103)
104%
(93 to 116)
85%
(81 to 89)
82%
(76 to 88)
(CPFE vs Other-SSc)†
(CPFE vs SSc-Emphysema)†
(SSc-ILD vs SSc-Emphysema)†
(Other-SSc vs SSc-ILD)†
DLco-predicted, mean (95% 
CI)
65%
(63 to 67)
73%
(70 to 75)
63%
(55 to 65)
61%
(58 to 64)
48%
(42 to 55)
(CPFE vs Other-SSc)†
(CPFE vs SSc-ILD)†
(CPFE vs SSc-Emphysema)**
(SSc-Other vs SSc-Emphysema)*
(Other-SSc vs SSc-ILD)***
DLco/VA-predicted, mean 
(95% CI)
82%
(80 to 85)
85%
(81 to 88)
83%
(75 to 91)
85%
(81 to 89)
59%
(52 to 67)
(CPFE vs SSc-ILD)†
(CPFE vs Other-SSc)†
(CPFE vs SSc-Emphysema)†
ILD extent >20%, n (%) 95 (20) 0 (0) 0 (0) 74 (38) 21 (49) (CPFE vs Other-SSc)§
(CPFE vs SSc-Emphysema)§
(SSc-ILD vs SSc-Emphysema)§
(Other-SSc vs SSc-ILD)§
sQCT of ILD, median (95% 
CI)
1%
(0 to 3)
0 0 15%
(13 to 17)
20%
(18 to 26)
(CPFE vs Other-SSc)†
(CPFE vs SSc-ILD)**
(CPFE vs SSc-Emphysema)†
(SSc-ILD vs SSc-Emphysema)†
(Other-SSc vs SSc-ILD)***
sQCT of emphysema, median 
(95% CI)
0 0 4%
(2 to 10)
0 4%
(2 to 7)
(CPFE vs SSc-ILD)†
(CPFE vs Other-SSc)†
(SSc-Emphysema vs SSc-ILD)†
(SSc-Emphysema vs Other-SSc)†
A graphical presentation of key findings is in the online supplementary file 1.
*<0.05; **<0.01; ***<0.001.
†<0.005.
‡Ten patients had an unknown smoke habit.
§<0.0001.
ACA, anticentromere antibodies; CPFE, combined pulmonary fibrosis and emphysema; DLco, diffusion lung capacity of CO; FVC, forced vital 
capacity; ILD, interstitial lung disease; IPF, Idiopathic pulmonary fibrosis; SSc, systemic sclerosis; TLC, Total lung capacity; VA, alveolar volume.
of SSc-ILD affected by severe emphysema.6 Recently, 
Antoniou et al described the characteristics of a cohort of 
SSc-CPFE.7 These patients had almost normal FVC and 
a DLco considerably decreased. These findings arise a 
discussion on the possible bias that FVC assessment and 
lack of pulmonary hypertension measurement could 
generate in this subgroup of SSc-ILD but were inconclu-
sive about CPFE role in SSc.8 Especially, it remains not 
clear if CPFE is associated with a decreased survival in 
SSc.
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Figure 1 Survival in SSc-CPFE, SSc-ILD, SSc-emphysema 
and other-SSc. CPFE, combined pulmonary fibrosis and 
emphysema; ILD, interstitial lung disease; SSc, systemic 
sclerosis.
The main aim of this study was to investigate the overall 
mortality of CPFE in patients with SSc. The secondary 
objective was to compare SSc-CPFE characteristics 
versus those of patients with SSc affected by ILD (SSc-
ILD), emphysema (SSc-emphysema) or neither of them 
(other-SSc).
MeTHOds
This study was conducted according to the Declaration of 
Helsinki. The Institutional Review Boards approved the 
study protocol; all patients provided informed consent.
Patients
Four-hundred and seventy (470) consecutive patients 
fulfilling the ACR/EULAR classification criteria9 for SSc 
were enrolled. Exclusion criteria were age <18 years and 
follow-up data available. The survival time was considered 
the time interval between the CT date and the death or 
the last clinic visit.
Pulmonary function tests
FVC and DLco performed within 6 months from CT were 
recorded. All centres performed PFTs according to the 
ATS/ERS standards.
sQCT assessments
Three thoracic radiologists scored the CT images as 
previously proposed.7 On the basis of the sQCT, four 
subgroups were identifies: (1) SSc-other (neither ILD nor 
emphysema); (2) SSc-emphysema (exclusive presence of 
emphysema); (3) SSc-ILD (exclusive presence of ILD); 
(4) CPFE (presence of ILD and emphysema).
statistical analysis
Statistical analysis was performed using R (http://www. 
r- project. org, V.3.3.3). Kaplan-Meier survival analysis and 
log-rank test verified the difference between the four 
subgroups. The HR with 95% CI was calculated according 
to Klein & Moeschberger method. P<0.05 was considered 
statistically significant.
More information are in the online supplementary file 
1.
ResulTs
This study included 1959 patient-year with a median 
follow-up of 4.2 (CI 3.9 to 4.3) years; 15% of patients 
(72/470) died. Patients’ characteristics are listed in 
table 1.
CPFE prevalence was 18% in patients with ILD and 7% 
in never smokers. Patients with CPFE had the highest 
male prevalence and the lowest DLco (p<0.05). CPFE 
and SSc-ILD had a similar autoimmune profile, which was 
different from patients with SSc-emphysema and other 
SSc (p<0.0005). In CPFE, there was a more relevant lung 
impairment (fibrosis extent and pulmonary function 
decrease) than in the other three subgroups (p<0.01). In 
SSc-emphysema, we observed the highest anticentromere 
antibodies prevalence (p<0.05) and a DLco decrease 
(similar to SSc-ILD, lower than in other-SSc and higher 
than in SSc-CPFE), while FVC was normal (higher than 
in SSc-CPFE and SSc-ILD). The extent of emphysema was 
similar in the SSc-CPFE and SSc-emphysema subgroups.
The Kaplan-Meier survival analysis demonstrated a 
worse survival in SSc-CPFE compared with other-SSc 
(p<0.01) and SSc-ILD or SSc-emphysema (p=0.1) 
(figure 1). The HR was, respectively, 2.8 (CI 1.2 to 6.6), 
1.6 (CI 0.7 to 3.8) and 1.6 (IC 0.5–5.2).
dIsCussIOn
This is the largest population of CPFE related to SSc 
ever described. Our observations about pulmonary func-
tion impairment, disease duration and smoke habit are 
similar to those of previous studies.5–7 We confirm that 
CPFE decreases gas exchange more than ILD or emphy-
sema alone; on the other hand, pulmonary static volumes 
are little or not affected.
Lung impairment (ILD, emphysema or both of them) 
appears to be related to a higher risk of death and a 
decrease of pulmonary function. ILD is a predictor of 
mortality,1 while emphysema presence was never taken 
into account. The detection of emphysema in never 
smokers was so far neglected, yet we showed that it 
deserves clinical attention.
Our findings confirm previous hypothesis about the 
role of emphysema in patients with SSc with pulmo-
nary fibrosis that namely it is a synergistic risk factor.5 
So, emphysema combined with pulmonary fibrosis is a 
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radiological pattern that should be considered in chest 
CT assessment. CPFE detection can be useful in order to 
select patients with an increased risk of mortality related 
to more severe SSc.
This study has the limitations of a retrospective design. 
In particular, there was not a control group of IPF-CPFE 
subjects, only two antibody patterns were recorded as far 
as the smoke habit duration (that is likely to have been a 
risk factor for emphysema onset). Moreover, the defini-
tion of CPFE is not clear. In the first studies, CPFE diag-
nosis was based on imaging features.5 We classified CPFE 
if sQCT of ILD and emphysema was ≧1%, as Antoniou et 
al proposed.7 However, this approach does not take into 
account the emphysema type, distribution and proximity 
to fibrotic lesions. Walsh et al10 showed that traction bron-
chiectasis are strongly associated with mortality in ILD 
related to connective tissue disease. So it is impossible to 
exclude that emphysema-like lesions near to fibrosis are 
an expression of ILD severity.
In conclusion, CPFE increases the risk of mortality and 
it should always be sought in order to better outline the 
prognosis in patients with SSc.
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